Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of NASDAQ:LPCN opened at $3.54 on Friday. The business’s fifty day moving average price is $3.79 and its two-hundred day moving average price is $4.53. Lipocine has a fifty-two week low of $2.91 and a fifty-two week high of $11.79. The stock has a market capitalization of $18.94 million, a price-to-earnings ratio of -4.66 and a beta of 1.42.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC grew its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 as of its most recent filing with the Securities and Exchange Commission. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.